Literature DB >> 21882915

Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience.

Mark Van Poppel1, Paul Klimo, Mariko Dewire, Robert A Sanford, Frederick Boop, Alberto Broniscer, Karen Wright, Amar J Gajjar.   

Abstract

OBJECT: Brain tumors in infants are often large, high grade, and vascular, making complete resection difficult and placing children at risk for neurological complications and excessive blood loss. Neoadjuvant chemotherapy may reduce tumor vascularity and volume, which can facilitate resection. The authors evaluated how an ongoing institutional prospective chemotherapy trial would affect patients who did not have a gross-total resection (GTR) immediately and who therefore required further surgical intervention to achieve definitive tumor resection.
METHODS: Thirteen infants (4 girls and 9 boys) who were enrolled in an institutional protocol in which they were treated with multiagent chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide with vinblastine for high-risk patients) subsequently underwent second-look surgery. The primary outcome was extent of resection achieved in postchemotherapy surgery. Secondary outcomes included intraoperative blood loss, radiographic response to the chemotherapy, complications during chemotherapy, and survival.
RESULTS: Three infants underwent biopsy, 9 underwent subtotal resection, and 1 patient did not undergo surgery prior to chemotherapy. On subsequent second-look surgery, 11 of 13 patients had a GTR, 1 had a near-total resection, and 1 had a subtotal resection. In each case, a marked reduction in tumor vascularity was observed intraoperatively. The average blood loss was 19% of estimated blood volume, and 6 (46%) of 13 patients required a blood transfusion. Radiographically, chemotherapy induced a reduction in tumor volume in 9 (69%) of 13 patients. Emergency surgery was required in 2 patients during chemotherapy, 1 for intratumoral hemorrhage and 1 for worsening peritumoral edema. The average follow-up period for this cohort was 16.5 months, and at last follow-up, 4 patients (31%) had died, 1 patient had progressive metastatic spinal disease, and the rest had either no evidence of disease or stable disease.
CONCLUSIONS: A GTR of pediatric brain tumors is one of the most important predictors of outcome. The application of the authors' neoadjuvant induction chemotherapy protocol in a variety of tumor types resulted in devascularization of all tumors and volume regression in the majority, and subsequently facilitated resection, with acceptable intraoperative blood loss. Intracranial complications may occur during chemotherapy, ranging from incidental and asymptomatic to life threatening, necessitating close monitoring of these children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21882915     DOI: 10.3171/2011.6.PEDS11158

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  14 in total

1.  Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34.

Authors:  Douglas R Strother; Lucie Lafay-Cousin; James M Boyett; Peter Burger; Patricia Aronin; Louis Constine; Patricia Duffner; Mehmet Kocak; Larry E Kun; Marc E Horowitz; Amar Gajjar
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

2.  Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.

Authors:  Santhosh A Upadhyaya; Giles W Robinson; Arzu Onar-Thomas; Brent A Orr; Catherine A Billups; Daniel C Bowers; Anne E Bendel; Tim Hassall; John R Crawford; Sonia Partap; Paul G Fisher; Ruth G Tatevossian; Tiffany Seah; Ibrahim A Qaddoumi; Anna Vinitsky; Gregory T Armstrong; Noah D Sabin; Christopher L Tinkle; Paul Klimo; Danny J Indelicato; Frederick A Boop; Thomas E Merchant; David W Ellison; Amar Gajjar
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

3.  Preoperative chemotherapy in medulloblastoma: a change in treatment paradigm?

Authors:  Dong-Anh Khuong-Quang; Jordan R Hansford
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

4.  Neoadjuvant chemotherapy for atypical teratoid rhabdoid tumors (AT/RTs).

Authors:  Eitaro Ishisaka; Kenichi Usami; Chikako Kiyotani; Keita Terashima; Hideki Ogiwara
Journal:  Childs Nerv Syst       Date:  2019-11-20       Impact factor: 1.475

5.  The impact of surgical resection of giant supratentorial brain tumor in pediatric patients: safety and neurological outcome evaluated in 23 consecutive cases.

Authors:  Ricardo Santos de Oliveira; Danilo Jorge Pinho Deriggi; Luciano L Furlanetti; Marcelo Volpon Santos; Elvis Terci Valera; Maria Sol Brassesco; Hélio Rubens Machado
Journal:  Childs Nerv Syst       Date:  2014-11-06       Impact factor: 1.475

6.  Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.

Authors:  Bruce H Cohen; J Russell Geyer; Douglas C Miller; John G Curran; Tianni Zhou; Emi Holmes; Sue Ann Ingles; Ira J Dunkel; Joanne Hilden; Roger J Packer; Ian F Pollack; Amar Gajjar; Jonathan L Finlay
Journal:  Pediatr Neurol       Date:  2015-04-09       Impact factor: 3.372

7.  Current treatment options for pediatric and adult patients with ependymoma.

Authors:  Karen D Wright; Amar Gajjar
Journal:  Curr Treat Options Oncol       Date:  2012-12

Review 8.  Neonatal Brain Tumors: A Review.

Authors:  Shaam Bodeliwala; Vikas Kumar; Daljit Singh
Journal:  J Neonatal Surg       Date:  2017-04-15

Review 9.  ETMR: a tumor entity in its infancy.

Authors:  Sander Lambo; Katja von Hoff; Andrey Korshunov; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2020-06-29       Impact factor: 17.088

10.  Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.

Authors:  Léa Guerrini-Rousseau; Rachid Abbas; Sophie Huybrechts; Virginie Kieffer-Renaux; Stéphanie Puget; Felipe Andreiuolo; Kévin Beccaria; Thomas Blauwblomme; Stéphanie Bolle; Frédéric Dhermain; Audrey Longaud Valès; Thomas Roujeau; Christian Sainte-Rose; Arnault Tauziede-Espariat; Pascale Varlet; Michel Zerah; Dominique Valteau-Couanet; Christelle Dufour; Jacques Grill
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.